ZVRA

Zevra Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 9/10
  • Value↑ 7/10
Zevra Therapeutics sales and earnings growth
ZVRA Growth
Great
  • Revenue Y/Y↑ 350.91%
  • EPS Y/Y↑ 161.40%
  • FCF Y/Y↑ 97.15%
Zevra Therapeutics gross and profit margin trends
ZVRA Profitability
Great
  • Gross margin ↑ 84.50%
  • EPS margin↑ 78.20%
  • ROIC 5Y↑ -50.45%
Zevra Therapeutics net debt vs free cash flow
ZVRA Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.4
  • Interest coverage↑ 11.9

Zevra Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗